Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

Conclusions:
Rituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/NF155 antibodies who are resistant to conventional therapies.

Classification of evidence:
This study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies.

Source: Neurology Neuroimmunology and Neuroinflammation - September 3, 2015 Category: Neurology Authors: Querol, L., Rojas-Garcia, R., Diaz-Manera, J., Barcena, J., Pardo, J., Ortega-Moreno, A., Sedano, M. J., Sero-Ballesteros, L., Carvajal, A., Ortiz, N., Gallardo, E., Illa, I. Tags: Class IV, Chronic inflammatory demyelinating polyneuropathy Article Source Type: research